Seer, Inc.
SEER Nasdaq Laboratory Analytical Instruments Financials FY2020βFY2025
What Seer, Inc. does
No business description yet.
- Legal name
- Seer, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 2, 2026
- Accession Β· CIK
- 0001193125-26-085481
0001726445
Revenue and margins
Seer, Inc. had $16.6M of revenue in fiscal 2025, up 17.0% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$46.2M in fiscal 2025, β279.0% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Seer, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 0.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably Seer, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $400M | $421M | $316M | $236M | $186M |
| Interest coverage | β3,248.8x | β | β | β | β |
| Current ratio | 30.7x | 34.6x | 25.0x | 16.5x | 12.8x |
| Quick ratio | 30.4x | 34.2x | 24.7x | 16.0x | 12.3x |
| Total assets | $539M | $488M | $436M | $367M | $296M |
| Total liabilities | $36.2M | $40.9M | $39.4M | $39.0M | $36.8M |
| Shareholders' equity | $503M | $447M | $397M | $328M | $259M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 8 | 3 / 8 | 3 / 8 | 2 / 7 | 3 / 7 |
| Accruals ratio | β2.7% | β5.1% | β6.3% | β5.9% | β10.1% | β8.8% |
| Altman Z'' | 47.70 | 17.77 | 14.34 | 11.48 | 7.75 | 4.62 |
6 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $0.7M | $6.6M | $15.5M | $16.7M | $14.2M | $16.6M |
| Gross profit | $0.7M | $3.4M | $7.1M | $8.5M | $7.1M | $8.5M |
| Research and development | $18.9M | $29.1M | $45.8M | $53.0M | $50.6M | $43.9M |
| Operating income | β$33.6M | β$71.5M | β$97.2M | β$103M | β$100M | β$78.0M |
| Interest expense | $0.0M | $0.0M | $0.0M | β | β | β |
| Pretax income | β | β | β | β$86.3M | β$86.5M | β$73.4M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.2M |
| Net income | β$32.8M | β$71.2M | β$93.0M | β$86.3M | β$86.6M | β$73.6M |
| Net income to common | β$32.8M | β$71.2M | β | β | β | β |
| Diluted EPS | β$2.48 | β$1.17 | β$1.49 | β$1.35 | β | β |
| Diluted shares | 0.01B | 0.06B | 0.06B | 0.06B | β | β |
| Cash flow | ||||||
| Cash from operations | β$20.8M | β$46.3M | β$60.8M | β$59.1M | β$46.1M | β$44.4M |
| Capital expenditure | $4.5M | $6.9M | $10.3M | $7.3M | $3.6M | $1.8M |
| Free cash flow | β$25.4M | β$53.3M | β$71.0M | β$66.4M | β$49.7M | β$46.2M |
| Depreciation and amortization | $1.6M | $2.6M | $3.9M | $5.4M | $5.8M | $5.1M |
| Stock-based compensation | $7.3M | $25.9M | $33.7M | $34.4M | $28.2M | $15.4M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β |
| Dividends and buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β |
| Balance sheet | ||||||
| Cash and short-term investments | $432M | $400M | $421M | $316M | $236M | $186M |
| Current assets | $433M | $412M | $435M | $331M | $253M | $202M |
| Current liabilities | $8.1M | $13.4M | $12.6M | $13.2M | $15.3M | $15.7M |
| Inventory | $0.6M | $4.1M | $4.6M | $4.5M | $7.4M | $7.8M |
| Property and equipment, net | $8.4M | $13.1M | $19.4M | $22.2M | $18.6M | $14.8M |
| Total assets | $442M | $539M | $488M | $436M | $367M | $296M |
| Total liabilities | $10.7M | $36.2M | $40.9M | $39.4M | $39.0M | $36.8M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $432M | $503M | $447M | $397M | $328M | $259M |
| Margins | ||||||
| Gross margin | 100.0% | 51.6% | 45.8% | 51.1% | 49.8% | 51.1% |
| Operating margin | β5,129.4% | β1,080.1% | β627.6% | β621.0% | β706.4% | β470.5% |
| EBITDA margin | β4,885.5% | β1,040.8% | β602.4% | β588.9% | β665.2% | β439.6% |
| Net margin | β4,996.2% | β1,075.5% | β600.1% | β517.8% | β611.1% | β444.0% |
| FCF margin | β3,866.2% | β805.0% | β458.6% | β398.4% | β350.7% | β279.0% |
| Returns | ||||||
| Return on capital employed | β7.7% | β13.6% | β20.5% | β24.5% | β28.5% | β27.8% |
| Return on equity | β7.6% | β15.2% | β19.6% | β20.4% | β23.9% | β25.1% |
| Return on assets | β7.4% | β14.5% | β18.1% | β18.7% | β21.6% | β22.2% |
| Return on tangible equity | β7.6% | β14.2% | β20.8% | β21.7% | β26.4% | β28.4% |
| Growth | ||||||
| Revenue growth | β | 908.7% | 134.1% | 7.5% | β15.0% | 17.0% |
| Share count change | β | 360.5% | 2.6% | 2.3% | β | β |
| Financial health | ||||||
| Interest coverage | β | β3,248.8x | β | β | β | β |
| Current ratio | 53.5x | 30.7x | 34.6x | 25.0x | 16.5x | 12.8x |
| Quick ratio | 53.4x | 30.4x | 34.2x | 24.7x | 16.0x | 12.3x |
| Capital allocation | ||||||
| Capex / revenue | 691.2% | 104.6% | 66.3% | 43.9% | 25.3% | 10.8% |
| Stock comp / revenue | 1,120.1% | 391.8% | 217.3% | 206.6% | 199.1% | 93.0% |
| Quality scores | ||||||
| Piotroski F-score | β | 2.0 | 3.0 | 3.0 | 2.0 | 3.0 |
| Altman Z'' | 47.7 | 17.8 | 14.3 | 11.5 | 7.7 | 4.6 |
| Accruals ratio | β2.7% | β5.1% | β6.3% | β5.9% | β10.1% | β8.8% |
Source: SEC EDGAR XBRL filings (CIK 0001726445). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.